DMO
IV PO
1 7
5 20 15
Key PCA Settings to Program
Every PCA order requires these 5 parameters:
Drug and concentration — e.g., hydromorphone 1 mg/mL
Demand (bolus) dose — the amount delivered each time the patient presses the button
Lockout interval — minimum time between doses (the pump ignores button presses during this period)
Basal (continuous) rate — optional background infusion running continuously
Hourly or 4-hour limit — maximum cumulative dose allowed in a set time period
Calculating PCA Settings for This Patient
This patient is highly opioid-tolerant — on methadone 10 mg PO q8h (30 mg/day) plus oxycodone 30 mg PO q4h PRN. The NHLBI guidelines recommend calculating the parenteral opioid dose based on the total daily short-acting opioid dose currently being taken at home. The key principle: continue the home methadone (it should not be discontinued) and build the PCA on top of it to cover the short-acting component.
Step 1: Continue home methadone 10 mg PO q8h
Methadone provides the long-acting baseline and has NMDA-receptor antagonist properties beneficial in SCD pain. Abrupt discontinuation risks withdrawal and undertreated pain.
Step 2: Convert the short-acting opioid (oxycodone) to IV hydromorphone
The patient took oxycodone 30 mg × 3 doses on the day of presentation (90 mg PO oxycodone). Using standard equianalgesic conversions:
PO oxycodone 90 mg/day → PO hydromorphone equivalent: 90 mg × 0.4 conversion factor = 36 mg PO hydromorphone/day
PO to IV hydromorphone ratio is approximately 5:1 (some sources use 4:1), so: 36 mg ÷ 5 = ~7.2 mg IV hydromorphone/day
Since pain was not controlled on this home regimen (the reason for presentation), starting at 100% of the equianalgesic dose (rather than reducing by 25–50%) is appropriate.
Step 3: Distribute into PCA settings
There are two main approaches:
Option A: Basal rate + demand dosing (favored by many SCD experts)
| Drug/concentration | Hydromorphone 1 mg/mL | Preferred over morphine in SCD (less histamine release) | |
| Basal (continuous) rate | 0.3 mg/hr (~7.2 mg/24h) | Covers the short-acting opioid equivalent; prevents nighttime pain breakthroughs | |
| Demand (bolus) dose | 0.3–0.4 mg (~10–20% of hourly total opioid) | For breakthrough pain on top of basal | |
| Lockout interval | 10–20 minutes | American Pain Society recommends q20 min; some institutions use q10 min | |
| 4-hour limit | 6–8 mg | Safety ceiling; adjust based on response |
Option B: Demand-only PCA (no basal rate) + continue home methadone
| Drug/concentration | Hydromorphone 1 mg/mL | — | |
| Basal rate | None (0 mg/hr) | Methadone provides the continuous coverage | |
| Demand dose | 0.4–0.6 mg | Higher demand dose needed since no basal; based on prior effective doses | |
| Lockout interval | 8–15 minutes | Shorter lockout since no basal infusion | |
| 4-hour limit | 6–8 mg | Safety ceiling |
Important Considerations for This Patient
Methadone creates unique challenges. Research shows that patients maintained on methadone are highly insensitive to the analgesic effects of hydromorphone — one study found that even cumulative IV hydromorphone doses of 32 mg failed to produce analgesia in patients on methadone 80–100 mg/day. While this patient is on a lower methadone dose (30 mg/day), this underscores the need for aggressive titration and close monitoring rather than conservative dosing.
Titration protocol: If the patient uses demand doses >3 times in 2 hours, tally the total opioid used in the last hour, set that as the new basal rate, and add demand doses on top. Dose escalation of 25% per reassessment is recommended until pain is controlled.
Monitoring requirements while on PCA:
Respiratory rate, sedation level (e.g., Pasero Opioid-Induced Sedation Scale), and SpO₂ every 1–2 hours for the first 24 hours
Continuous pulse oximetry is recommended, especially with a basal rate
Pain reassessment with each nursing check
Naloxone at bedside
The current order of hydromorphone 1.4 mg IV q4h PRN is likely inadequate for this patient's level of opioid tolerance and should be converted to a PCA with the settings above, in consultation with hematology and/or the acute pain service.
Below is a comprehensive study guide on sickle cell disease management with key terms bolded as cloze deletions for active recall.
Terminology to Avoid
Terms to avoid when discussing sickle cell patients include "sickers" (pejorative connotation), "pain crisis" (the preferred term is vaso-occlusive pain episode), and "frequent flyer" — instead, quantify the number of ED visits or hospitalizations (e.g., "8 ED visits in the past year").
Initial Evaluation and Analgesia
Analgesia should not be delayed. The ASH 2020 guidelines recommend analgesia within 60 minutes of ED arrival, with reassessments every 30–60 minutes. The NHLBI guidelines recommend even faster — within 30 minutes. Typical first-line parenteral opioids include IV morphine (starting dose 0.1 mg/kg) or IV hydromorphone (starting dose 0.015 mg/kg). If pain is not relieved after 3 or more doses, the patient should be admitted.
There are no objective signs or laboratory values that can diagnose or quantify a sickle cell pain episode — the patient's self-report of pain is the criterion standard. Reticulocyte count, hemolysis markers, and anemia levels do not correlate with pain severity.
Opioid use disorder rates in sickle cell patients are actually lower than or comparable to the general population, and pain should be treated aggressively without stigma.
Duration and Atypical Pain
The average hospital stay for an acute pain episode is 7 days in adults and 4.5 days in children. If pain persists beyond 10 days, alternative causes should be investigated (e.g., gout, rotator cuff injury, depression).
The most common pain locations are the chest, back, abdomen, and long bones. If pain is atypical from the patient's usual episodes, consider secondary complications:
Multi-site pain → multi-organ failure, rapidly progressive acute chest syndrome, or transfusion reactions
Headache → stroke, intracranial hemorrhage, or meningitis
Atypical chest pain → acute chest syndrome, PE, or cardiac ischemia
Severe abdominal pain → splenic or hepatic sequestration, pancreatitis, UTI, cholecystitis
Severe extremity pain → avascular necrosis, DVT, or osteomyelitis
Inpatient Pain Management: PCA
Once admitted, patients should be started on patient-controlled analgesia (PCA), which reduces delays in medication delivery and is considered safer — if a patient becomes obtunded or develops respiratory depression, they will not press the PCA button.
Regarding basal dosing: the American Pain Society recommends a basal rate, while the ASH 2020 guidelines offer no recommendation for or against basal dosing. Multiple experts favor a basal rate to prevent uncontrolled nighttime pain and improve sleep quality. The recommended PCA lockout interval is every 20 minutes per the American Pain Society.
Dosing strategies:
Initial dosing should be based on prior opioid needs (individualized dosing reduces admission rates — 40.3% vs 57.5% with weight-based dosing)
Alternatively, continue the patient's home long-acting opioid and add PRN/demand PCA on top
The PRN demand dose should be approximately 1/16th of the basal dose
Dose escalation: If the patient uses demand doses more than 3 times in the last 2 hours, tally the total opioid use over the last hour, set that as the new basal rate, and add PRN demand doses on top.
Tapering Strategy
Do not taper in the first 24 hours unless there is significant respiratory depression or lethargy
Taper during the daytime (not nighttime) for frequent reassessment
Taper incrementally: 10–20% of the dose at a time
Decrease the dose rather than increasing the lockout interval
Convert to oral medications once the IV dose is approximately equivalent to the home oral regimen (use morphine milligram equivalent (MME) calculators to compare)
The AAFP recommends initiating weaning when the patient reports pain less than 5 on a visual analog scale
Adjunctive Pharmacotherapy
Ketamine — an NMDA receptor antagonist with weak activity at mu and kappa opioid receptors and an antidepressant effect. ASH 2020 conditionally recommends subanesthetic ketamine for pain refractory to opioids alone. Dosing options:
IV continuous infusion: 0.1–0.3 mg/kg/hour (max 1 mg/kg/hour)
Intranasal: 0.25 mcg/kg
PO: start at 10–15 mg q6h, increase by 10 mg q6h daily
Side effects: tachycardia, hypertension, elevated LFTs, hallucinations/emergence reactions (more common at anesthetic doses)
Studies show ketamine reduces pain scores within 24 hours and decreases cumulative opioid requirements.
NSAIDs — ASH suggests a short course of 5–7 days. However, the UpToDate expert panel does not recommend routine use due to lack of RCTs showing efficacy with concurrent opioids and a >63% increased risk of acute or chronic kidney injury.
Fluids — No strong evidence for routine IV fluids. Give fluids based on volume status and clinical assessment; a pain episode alone does not warrant continuous fluids if the patient is euvolemic.
Methadone — a long-acting opioid with neuropathic pain benefit, useful as an adjunct in sickle cell pain episodes.
Corticosteroids — ASH suggests against corticosteroids for pain management.
Pruritus Management
IV opioids activate mast cells and release histamine (more with IV morphine than IV hydromorphone). Treatment:
Use PO antihistamines (e.g., hydroxyzine, diphenhydramine)
Avoid IV diphenhydramine — it can cause a euphoric/high effect
For refractory pruritus: continuous low-dose naloxone at 0.25 mcg/kg/min (does not reverse analgesia at this dose)
Adjunctive Non-Pharmacologic Therapies
Heat packs preferred; avoid cold packs (cold induces sickling)
Psychosocial support, emotional counseling, insomnia treatment
ASH recommends SNRIs (e.g., duloxetine) especially for avascular necrosis and chronic pain
TCAs also suggested for chronic pain (evidence extrapolated from fibromyalgia literature)
ASH suggests massage, yoga, TENS, virtual reality, guided audiovisual relaxation, and CBT
Transfusions
Simple transfusion = infusion of packed RBCs without removal of patient blood. Exchange transfusion = removal of patient blood and replacement with donor blood to reduce HbS percentage.
Transfusion thresholds in SCD differ from the general population — do not use the typical <7 g/dL threshold. Instead, transfuse when hemoglobin is <5 g/dL in adults, or >1–2 g/dL below baseline, or with symptomatic anemia.
Indications for exchange transfusion: stroke, severe acute chest syndrome (SpO₂ <90% despite O₂, rapidly progressive disease), and multi-organ failure. The goal HbS after exchange transfusion is <30%.
Preoperative transfusion goal: hemoglobin >10 g/dL. Prophylactic transfusions during pregnancy: not routinely indicated, but prophylactic transfusions are indicated for patients with prior stroke, ACS, priapism, or pulmonary hypertension — reducing stroke risk by approximately 50%.
Risks of transfusion in SCD:
Iron overload (chelation recommended when ferritin >1,000 ng/mL or after 10 units transfused)
Alloimmunization (~11% of chronically transfused patients) — reduced by matching for D, C, E, and Kell antigens
Hemolytic transfusion reactions (acute or delayed)
Hyperhemolytic syndrome
Hyperviscosity → stroke risk
Iron chelation: The preferred first-line agent is deferasirox (oral, once daily) due to better adherence, not deferoxamine. Deferiprone is an alternative oral agent (three times daily, requires monitoring for agranulocytosis). Deferoxamine (subcutaneous/IV) is reserved for renal impairment or cardiac iron overload.
Outpatient/Maintenance Medications
The following table from a 2022 JAMA review summarizes the approved therapies:
Hydroxyurea — the only medication shown to decrease mortality in SCD. It is a ribonucleotide reductase inhibitor that increases hemoglobin F (HbF), which inhibits HbS polymerization, reduces sickling, and improves oxygen delivery. It also increases nitric oxide, decreases red cell adhesion, and decreases leukocyte counts. First-line for all patients with HbSS or HbSβ⁰-thalassemia starting at 9 months of age. Monitoring: track MCV — expect macrocytosis (MCV in the 100s); a low MCV on hydroxyurea suggests non-adherence.
L-glutamine — increases antioxidant activity in RBCs, reduces pain episodes by 25% and hospitalization by 33%.
Crizanlizumab — monoclonal antibody against P-selectin, prevents interaction between endothelial cells and sickled RBCs. Reduced pain crises from 2.98 to 1.63/year.
Voxelotor — IMPORTANT UPDATE: Voxelotor (Oxbryta) was voluntarily withdrawn from the market by Pfizer due to an imbalance in vaso-occlusive crises and fatal events, indicating the overall benefit no longer outweighed the risk. This is a significant change from the video content.
All patients should also be on folic acid (and likely a multivitamin) due to chronic hemolysis and high bone marrow turnover. Screen routinely for pulmonary hypertension.
Sickle cell day infusion centers are preferred over the ED for pain episodes — they achieve faster opioid initiation (62 min vs 132 min) and lower admission rates (9% vs 37%).
Allogeneic hematopoietic stem cell transplant is the only curative therapy, with best results at younger ages and with a matched sibling donor.
Hemoglobin SC Disease
HbSC disease is sometimes considered more mild than HbSS, with a higher baseline hemoglobin, but patients can still have severe pain episodes requiring aggressive treatment. These patients have an increased risk for retinopathy and other ophthalmologic complications compared to HbSS — early ophthalmology screening is essential.
Acute Chest Syndrome (ACS)
Suspect ACS with a new radiodensity on chest imaging plus fever or respiratory symptoms (pleuritic chest pain, hypoxemia, tachypnea). Management:
Pain control and incentive spirometry
Maintain oxygen saturation >95% (NHLBI) or >92% (other sources)
Antibiotics: IV cephalosporin + oral macrolide (covers atypicals — Mycoplasma, Chlamydia)
Simple transfusion if hemoglobin is >1 g/dL below baseline
Exchange transfusion for severe/rapidly progressive ACS (SpO₂ <90% despite supplemental O₂, progressive infiltrates, declining hemoglobin) — target HbS <30%
The following figure illustrates a multimodal pain protocol for vaso-occlusive crisis management from the ED through hospital admission:
2020 ASH Guidelines Summary
Recommend rapid assessment and analgesia within 1 hour, reassessments q30–60 min (strong)
Suggest tailored opioid dosing based on baseline therapy (conditional)
Suggest short-course NSAIDs 5–7 days (conditional)
Suggest against corticosteroids for pain (conditional)
Suggest regional anesthesia for refractory localized pain (conditional)
No recommendation regarding IV fluids
Suggest massage, yoga, TENS, virtual reality, guided relaxation (conditional)
Suggest sickle cell–specific day hospitals/infusion centers over ED (conditional)
No recommendation for or against basal PCA dosing
Suggest duloxetine or other SNRIs for chronic pain, especially with AVN (conditional)
Suggest TCAs for chronic pain (conditional)
Suggest CBT and integrative approaches (massage, acupuncture) (conditional)
Suggest subanesthetic ketamine for opioid-refractory acute pain (conditional)
Would you like to explore the emerging role of gene therapy (e.g., lovotibeglogene autotemcel, exagamglogene autotemcel) as curative options for sickle cell disease and how they compare to allogeneic stem cell transplant?
Comments
Post a Comment